Vicore Pharma AB Revenue and Competitors
Estimated Revenue & Valuation
- Vicore Pharma AB's estimated annual revenue is currently $10.7M per year.
- Vicore Pharma AB's estimated revenue per employee is $201,000
Employee Data
- Vicore Pharma AB has 53 Employees.
- Vicore Pharma AB grew their employee count by 20% last year.
Vicore Pharma AB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | VP, Investor Relations, Communications, and Portfolio Strategy | Reveal Email/Phone |
5 | Head Quality Assurance | Reveal Email/Phone |
6 | VP, Business Development | Reveal Email/Phone |
7 | Director Digital Health | Reveal Email/Phone |
8 | Global Medical Director | Reveal Email/Phone |
9 | Senior CMC Manager | Reveal Email/Phone |
10 | Group Financial Controller | Reveal Email/Phone |
Vicore Pharma AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Vicore Pharma AB?
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
keywords:N/A
N/A
Total Funding
53
Number of Employees
$10.7M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.9M | 53 | 15% | N/A |
#2 | $6.2M | 53 | 18% | N/A |
#3 | $6.9M | 53 | N/A | N/A |
#4 | $6.7M | 53 | N/A | N/A |
#5 | $6.9M | 53 | N/A | N/A |